PE20211002A1 - Compuestos como moduladores de ror gamma - Google Patents

Compuestos como moduladores de ror gamma

Info

Publication number
PE20211002A1
PE20211002A1 PE2020001484A PE2020001484A PE20211002A1 PE 20211002 A1 PE20211002 A1 PE 20211002A1 PE 2020001484 A PE2020001484 A PE 2020001484A PE 2020001484 A PE2020001484 A PE 2020001484A PE 20211002 A1 PE20211002 A1 PE 20211002A1
Authority
PE
Peru
Prior art keywords
compounds
arylus
heteroaryl
ror gamma
refers
Prior art date
Application number
PE2020001484A
Other languages
English (en)
Spanish (es)
Inventor
Johanna Bakonyi
Steven Richard Brunette
Delphine Collin
Robert Owen Hughes
Xiang Li
Shuang Liang
Robert Sibley
Michael Robert Turner
Lifen Wu
Qiang Zhang
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20211002A1 publication Critical patent/PE20211002A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/10—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2020001484A 2014-04-14 2015-04-10 Compuestos como moduladores de ror gamma PE20211002A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461979231P 2014-04-14 2014-04-14
PCT/US2015/025328 WO2015160654A1 (en) 2014-04-14 2015-04-10 Compounds as modulators of ror gamma

Publications (1)

Publication Number Publication Date
PE20211002A1 true PE20211002A1 (es) 2021-06-01

Family

ID=52998264

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2020001484A PE20211002A1 (es) 2014-04-14 2015-04-10 Compuestos como moduladores de ror gamma
PE2016001963A PE20161572A1 (es) 2014-04-14 2015-04-10 Compuestos como moduladores de ror gamma

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2016001963A PE20161572A1 (es) 2014-04-14 2015-04-10 Compuestos como moduladores de ror gamma

Country Status (35)

Country Link
US (5) US9242989B2 (enExample)
EP (2) EP3131902B1 (enExample)
JP (2) JP6282759B2 (enExample)
KR (2) KR102410069B1 (enExample)
CN (3) CN107266450B (enExample)
AP (1) AP2016009403A0 (enExample)
AR (2) AR100058A1 (enExample)
AU (2) AU2015247983B2 (enExample)
BR (2) BR122020020657B1 (enExample)
CA (1) CA2944787C (enExample)
CL (1) CL2016002421A1 (enExample)
CY (1) CY1122012T1 (enExample)
DK (1) DK3131902T3 (enExample)
EA (2) EA035063B1 (enExample)
ES (1) ES2744299T3 (enExample)
HR (1) HRP20191579T1 (enExample)
HU (1) HUE045847T2 (enExample)
IL (2) IL247419B (enExample)
LT (1) LT3131902T (enExample)
MA (1) MA46373A (enExample)
ME (1) ME03513B (enExample)
MX (1) MX370780B (enExample)
MY (1) MY182834A (enExample)
NZ (1) NZ723530A (enExample)
PE (2) PE20211002A1 (enExample)
PH (2) PH12016502019B1 (enExample)
PL (1) PL3131902T3 (enExample)
PT (1) PT3131902T (enExample)
RS (1) RS59170B1 (enExample)
SG (1) SG11201608537SA (enExample)
SI (1) SI3131902T1 (enExample)
TW (2) TWI652268B (enExample)
UA (2) UA121255C2 (enExample)
UY (1) UY36077A (enExample)
WO (1) WO2015160654A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122020020657B1 (pt) * 2014-04-14 2022-12-20 Boehringer Ingelheim International Gmbh Compostos, composição farmacêutica e seus usos como moduladores de ror gama
FR3030518B1 (fr) * 2014-12-19 2018-03-23 Galderma Research & Development Derives sulfonamides en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t)
KR102702236B1 (ko) 2015-05-15 2024-09-04 오리진 온콜로지 리미티드 Ror 감마 조절제로서의 치환된 테트라하이드로퀴놀리논 화합물
US10450314B2 (en) 2015-10-01 2019-10-22 Boehringer Ingelheim International Gmbh Pteridine derivatives as modulators of ROR gamma
KR101947976B1 (ko) 2015-12-15 2019-02-13 아스트라제네카 아베 이소인돌 화합물
EP3405470B1 (en) * 2016-01-20 2020-07-15 Boehringer Ingelheim International GmbH Pyrazinedihydropyrimidinone or pyridazinedihydropyrimidinone compounds as modulators of ror gamma
AR110481A1 (es) 2016-12-05 2019-04-03 Lead Pharma Holding Bv MODULADORES DE ROR g (RORg)
US20200031753A1 (en) 2017-04-06 2020-01-30 Boehringer Ingelheim International Gmbh Cyclopropyl alkyl amines and process for their preparation
EP3638661A1 (en) 2017-06-14 2020-04-22 Astrazeneca AB 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
CN109206346A (zh) * 2017-07-01 2019-01-15 复旦大学 叔胺类衍生物或其盐及其制备方法和用途
CN107903263B (zh) * 2017-12-28 2019-11-12 山东铂源药业有限公司 一种帕布昔利布中间体的合成方法
SMT202300212T1 (it) 2018-05-03 2023-09-06 Shanghai hengrui pharmaceutical co ltd Derivati di benzimidazolo come modulatori del recettore gamma orfano correlato al retinoide (rory) e usi farmaceutici di essi
US20210395185A1 (en) 2018-10-18 2021-12-23 Boehringer Ingelheim International Gmbh Scalable synthesis of optically active 1-cyclopropylalkyl-1-amines
WO2021061803A1 (en) 2019-09-23 2021-04-01 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
US20230014730A1 (en) 2019-09-23 2023-01-19 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
BR112022008293A2 (pt) 2019-10-31 2022-07-26 Jiangsu Hengrui Medicine Co Sal de adição de ácido de regulador de ror?, composições farmacêuticas, uso dos mesmos e métodos para preparar forma cristalina e composição farmacêutica
WO2022106548A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Solid forms of a ror gamma inhibitor
WO2022106549A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Crystalline salts of a ror gamma inhibitor
WO2022106547A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Process for synthesising a ror gamma inhibitor
WO2022106550A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Crystalline polymorphic form of a ror gamma inhibitor
WO2022106551A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Co-crystals of a ror gamma inhibitor
CN117003757A (zh) * 2022-05-07 2023-11-07 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为usp1抑制剂
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19
CN116178279A (zh) * 2023-03-15 2023-05-30 上海药坦药物研究开发有限公司 一种5-溴-4-环丙基-6-甲氧基嘧啶及其中间体的制备方法
AU2024267864A1 (en) * 2023-05-09 2025-11-06 11949098 Canada Inc. Inverse agonists of rar related orphan receptors (rors)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
WO2009022185A2 (en) * 2007-08-16 2009-02-19 Astrazeneca Ab 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use
PE20110854A1 (es) 2008-09-26 2011-12-23 Boehringer Ingelheim Int DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1
AP2012006204A0 (en) 2009-10-21 2012-04-30 Boehringer Ingelheim Int Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists.
BR112013030894A2 (pt) * 2011-06-01 2016-08-16 Janus Biotherapeutics Inc moduladores do sistema imune
CN106008511B (zh) * 2012-05-14 2018-08-14 华东理工大学 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用
BR122020020657B1 (pt) * 2014-04-14 2022-12-20 Boehringer Ingelheim International Gmbh Compostos, composição farmacêutica e seus usos como moduladores de ror gama
US10450314B2 (en) * 2015-10-01 2019-10-22 Boehringer Ingelheim International Gmbh Pteridine derivatives as modulators of ROR gamma
EP3405470B1 (en) * 2016-01-20 2020-07-15 Boehringer Ingelheim International GmbH Pyrazinedihydropyrimidinone or pyridazinedihydropyrimidinone compounds as modulators of ror gamma

Also Published As

Publication number Publication date
AU2015247983A1 (en) 2016-09-08
BR112016021962A2 (pt) 2023-01-20
MX370780B (es) 2020-01-03
US20160075706A1 (en) 2016-03-17
EP3418280B1 (en) 2023-07-12
AR100058A1 (es) 2016-09-07
JP2017511357A (ja) 2017-04-20
KR102410069B1 (ko) 2022-06-20
US9242989B2 (en) 2016-01-26
HK1244800A1 (zh) 2018-08-17
CA2944787A1 (en) 2015-10-22
CY1122012T1 (el) 2020-10-14
UY36077A (es) 2015-10-30
CA2944787C (en) 2023-03-14
US20170008894A1 (en) 2017-01-12
HRP20191579T1 (hr) 2019-11-29
IL247419B (en) 2019-03-31
IL263878A (en) 2019-01-31
JP2018065874A (ja) 2018-04-26
PH12016502019B1 (en) 2020-10-23
PL3131902T3 (pl) 2019-11-29
CN107266450B (zh) 2020-07-24
JP6282759B2 (ja) 2018-02-21
LT3131902T (lt) 2019-09-25
MY182834A (en) 2021-02-05
CN107266450A (zh) 2017-10-20
JP6463855B2 (ja) 2019-02-06
IL263878B (en) 2019-11-28
TW201625622A (zh) 2016-07-16
ES2744299T3 (es) 2020-02-24
US20180022749A1 (en) 2018-01-25
PH12016502019A1 (en) 2017-01-09
TWI655192B (zh) 2019-04-01
PH12020500252A1 (en) 2021-07-26
CN107266454A (zh) 2017-10-20
HK1244801A1 (zh) 2018-08-17
CN106132965A (zh) 2016-11-16
TWI652268B (zh) 2019-03-01
AU2015247983B2 (en) 2019-05-16
EA035063B1 (ru) 2020-04-23
EA031351B1 (ru) 2018-12-28
KR20200040917A (ko) 2020-04-20
KR20160142396A (ko) 2016-12-12
EA201890329A1 (ru) 2018-07-31
UA121255C2 (uk) 2020-04-27
AU2019203027B2 (en) 2020-07-09
EP3418280A1 (en) 2018-12-26
HUE045847T2 (hu) 2020-01-28
EP3131902B1 (en) 2019-06-12
MA46373A (fr) 2019-08-07
SI3131902T1 (sl) 2019-10-30
MX2016013342A (es) 2017-01-26
US9598415B2 (en) 2017-03-21
NZ723530A (en) 2023-05-26
TW201841915A (zh) 2018-12-01
ME03513B (me) 2020-04-20
WO2015160654A1 (en) 2015-10-22
PE20161572A1 (es) 2017-02-01
CN106132965B (zh) 2020-02-07
AP2016009403A0 (en) 2016-08-31
DK3131902T3 (da) 2019-09-02
EP3131902A1 (en) 2017-02-22
BR112016021962B1 (pt) 2022-12-13
AR119454A2 (es) 2021-12-22
US20150291607A1 (en) 2015-10-15
EA201691978A1 (ru) 2017-02-28
CN107266454B (zh) 2019-08-09
AU2019203027A1 (en) 2019-05-23
CL2016002421A1 (es) 2017-03-24
UA120094C2 (uk) 2019-10-10
SG11201608537SA (en) 2016-11-29
RS59170B1 (sr) 2019-10-31
PT3131902T (pt) 2019-09-17
BR122020020657B1 (pt) 2022-12-20
KR102410076B1 (ko) 2022-06-22
US20190002465A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
PE20161572A1 (es) Compuestos como moduladores de ror gamma
CL2018003323A1 (es) Piridinas sustituidas con heteroarilo y métodos de uso.
PE20142461A1 (es) Moduladores del receptor de estrogeno y sus usos
CY1122916T1 (el) Νεες ενωσεις ως ρυθμιστες ror γαμμα
ES2669189T3 (es) Compuestos de carbazol útiles como inhibidores del bromodominio
ES2869172T3 (es) Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro
NI201500130A (es) 2-azabiciclo sustituidos y su uso como moduladores del receptor de orexina
UY35908A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CU20170073A7 (es) Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos
MX2017001554A (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas oncologicas y autoinmunitarias.
CU20180144A7 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
AR103138A1 (es) Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos
PE20150182A1 (es) Compuestos de fenoxietil piperidina
PE20180483A1 (es) Oxiesteroles y metodos de uso de los mismos
MA43512A (fr) Composés hétérocycliques utiles en tant que modulateurs du tnf alpha
MX2016012719A (es) Uso de compuesto heterociclicos para controlar nematodos.
CO2019002692A2 (es) Nuevos derivados de isoxazolil éter como pam de gaba a alfa5.
GT201400275A (es) Tiazoles sustituidos por carboxamida o sulfonamida y derivados relacionados como moduladores para el receptor nuclear huèrfano rory
PE20180031A1 (es) Compuestos moduladores de receptor de tipo toll
ECSP16000724A (es) Carboxamidas de anillo de 4 miembros empleadas como nematicidas
PE20151606A1 (es) DERIVADOS DE NAFTIRIDINA UTILES COMO ANTAGONISTAS DE LA AvB6 INTEGRINA
MX2016007219A (es) Metodos novedosos.
CU24459B1 (es) 8-cloro-n-quinoleínas y sus derivados como activos antiinflamatorios
ES2678086T3 (es) Compuestos de diona cíclicos (alquil-fenil)-sustituidos activos como herbicidas y derivados de los mismos
AR103317A1 (es) Moduladores de ciclopropil dihidrobenzofurano de receptores de melatonina